SMO and pancreatic neoplasm: A trial with vismodegib in pancreatic cancer, in which Hh ligands are similarly overexpressed, had an equally discouraging outcome9, whereas a further pancreatic cancer study using another SMO antagonist was halted due to an inferior outcome in the inhibitor-treated group10.